Nippon Shinyaku (TSE:4516) Stock Looks Fairly Valued At Current Levels

Nippon Shinyaku Co., Ltd. 2027 Q1 - Results - Earnings Call Presentation (OTCMKTS:NPPNY) 2026-08-10

NS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 BIO's Tadekinig alfa in the U.S.

AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa

Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children's Hospital

All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6%

Regenxbio Shares Rise After Positive Duchenne Trial Results

Ionis: What Upside Is Left After Shares Rocketed Higher Following Positive Trial Data?

5 Reasons To Buy Regenxbio Right Now (NASDAQ:RGNX)